Physician profile
David A Evans
NPI 1083663629
$2,731.20
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,409 · 2020: $97.77 · 2021: $11.20 · 2022: $213.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,441.41 | 2019 | |
| Coopervision INC. | $262.54 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $206.96 | 2019 | |
| Allergan, INC. | $150.69 | 2019-2022 | |
| Spark Therapeutics, INC. | $124.99 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $120.02 | 2019 | |
| Kala Pharmaceuticals, INC. | $113.16 | 2021-2022 | |
| Optovue, INC. | $97.95 | 2019 | |
| Shire North American Group INC | $46.95 | 2019 | |
| Sun Pharmaceutical Industries INC. | $15.50 | 2022 | |
| Abbvie INC. | $14.05 | 2022 | |
| Carl Zeiss Meditec, INC. | $11.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.